Chengdu-based biopharmaceutical enterprise Chengdu Shiliankangjian Biotechnology Co., Ltd. has recently obtained approval from the Center for Drug Evaluation of the National Medical Products Administration for clinical trials of its independently developed new drug, “Human Dental Follicle Mesenchymal Stem Cell Injection (SLDSC001)”. This is the world’s first dental follicle mesenchymal stem cell therapy for periodontitis and marks Sichuan’s first stem cell drug approved for new drug clinical trials.

 

 

Edited by Zhang Yuanlin

Source:Chengdu Discovery